Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,060 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.
Zhang T, Tian W, Wei S, Lu X, An J, He S, Zhao J, Gao Z, Li L, Lian K, Zhou Q, Zhang H, Wang L, Su L, Kang H, Niu T, Zhao A, Pan J, Cai Q, Xu Z, Chen W, Jing H, Li P, Zhao W, Cao Y, Mi J, Chen T, Chen Y, Zou P, Lukacs-Kornek V, Kurts C, Li J, Liu X, Mei Q, Zhang Y, Wei J. Zhang T, et al. Among authors: su l. Exp Hematol Oncol. 2023 Jul 27;12(1):66. doi: 10.1186/s40164-023-00426-x. Exp Hematol Oncol. 2023. PMID: 37501090 Free PMC article. Review.
[Clinical analysis of seven cases of myeloid sarcoma].
Ma L, Zhao J, Wang JR, Gui W, Su LP. Ma L, et al. Among authors: su lp. Zhonghua Zhong Liu Za Zhi. 2019 May 23;41(5):389-392. doi: 10.3760/cma.j.issn.0253-3766.2019.05.013. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31137175 Chinese.
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Li P, Liu Y, Liang Y, Bo J, Gao S, Hu Y, Hu Y, Huang H, Huang X, Jing H, Ke X, Li J, Li Y, Liu Q, Lu P, Mei H, Niu T, Song Y, Song Y, Su L, Tu S, Wang J, Wu D, Wang Z, Xu K, Ying Z, Yang Q, Zhang Y, Shi F, Zhang B, Zhang H, Zhang X, Zhao M, Zhao W, Zhao X, Huang L, Zhu J, Qian W, Han W, Liang A. Li P, et al. Among authors: su l. Cancer Biol Med. 2023 Mar 2;20(2):129-46. doi: 10.20892/j.issn.2095-3941.2022.0585. Cancer Biol Med. 2023. PMID: 36861439 Free PMC article.
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.
Jian Y, Chang L, Shi MX, Sun Y, Chu XX, Xue H, Huang WR, Shen XL, Ma J, Jia GR, Feng YQ, Xi ZF, Zhao YH, Ma YP, Xiao J, Ma GY, Wang QM, Bao L, Dong YJ, Zhou HB, Sun CY, Su GH, Yan Y, Qimuge SY, Su LP, Sun JN, Tian WW, Sun XL, Ing HM, Gao D, Chen WM, Li J, Gao W. Jian Y, et al. Among authors: su gh, su lp. Blood Adv. 2023 Dec 26;7(24):7581-7584. doi: 10.1182/bloodadvances.2023011428. Blood Adv. 2023. PMID: 37922425 Free PMC article. No abstract available.
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.
Zhou H, Wang Y, Chen J, He A, Jin J, Lu Q, Zhao Y, Li J, Hou M, Su L, Lai X, Wang W, Liu L, Ma Y, Gao D, Lai W, Zhou X, Jing H, Zhang J, Yang W, Ran X, Lin C, Hao J, Xiao T, Huang Z, Zhu Z, Wang Q, Fang B, Wang B, Song Y, Cai Z, Liu B, Zhu Y, Yang X, Kang X, Li J, Chen W. Zhou H, et al. Among authors: su l. Ann Hematol. 2024 Mar;103(3):855-868. doi: 10.1007/s00277-023-05558-y. Epub 2023 Dec 19. Ann Hematol. 2024. PMID: 38112795 Free PMC article.
7,060 results